keyword
MENU ▼
Read by QxMD icon Read
search

Clinical trials in ibd

keyword
https://www.readbyqxmd.com/read/28922695/strategies-for-detecting-colon-cancer-in-patients-with-inflammatory-bowel-disease
#1
REVIEW
William A Bye, Tran M Nguyen, Claire E Parker, Vipul Jairath, James E East
BACKGROUND: Patients with longstanding ulcerative colitis and colonic Crohn's disease have an increased risk of colorectal cancer (CRC) compared with the general population. This review assessed the evidence that endoscopic surveillance may prolong life by allowing earlier detection of CRC or its pre-cursor lesion, dysplasia, in patients with inflammatory bowel disease (IBD). OBJECTIVES: To assess the effectiveness of cancer surveillance programs for diagnosis of IBD-associated colorectal cancer and in reducing the mortality rate from colorectal cancer in patients with IBD...
September 18, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28914446/risk-factors-for-thiopurine-induced-myelosuppression-and-infections-in-inflammatory-bowel-disease-patients-with-a-normal-tpmt-genotype
#2
M M T J Broekman, M J H Coenen, G J Wanten, C J van Marrewijk, O H Klungel, A L M Verbeek, P M Hooymans, H-J Guchelaar, H Scheffer, L J J Derijks, D R Wong, D J de Jong
BACKGROUND: Leucopenia is a common side effect in patients treated with thiopurines. Variants in the thiopurine S-methyltransferase (TPMT) gene are the best-known risk factor, but only explain up to 25% of leucopenia cases. AIM: To identify the clinical risk factors for thiopurine-induced leucopenia in patients without a common TPMT variant, and explore if these patients are at increased risk for infections. METHODS: Post hoc analysis of the Thiopurine response Optimisation by Pharmacogenetic testing in Inflammatory bowel disease Clinics (TOPIC) trial...
September 15, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28914206/mesenchymal-stem-cell-as-a-potential-therapeutic-for-inflammatory-bowel-disease-myth-or-reality
#3
Sanjucta Adak, Sayani Mukherjee, Dwaipayan Sen
BACKGROUND: Inflammatory bowel diseases (IBD), which include Crohn's disease and Ulcerative Colitis, are inflammatory autoimmune diseases which severely affect the quality of life. Till date, no long-lasting cure has been found for the disease and all the current treatment strategies are mainly focused on dampening the symptomatic inflammatory process that has certain side effects. In addition, a large number of patients remain refractory to conventional therapies. Mesenchymal stem cells (MSCs) can be looked upon as a biodrug to treat IBD owing to their immune-suppressive and regenerative capabilities...
September 13, 2017: Current Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28913325/bone-loss-prevention-of-bisphosphonates-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#4
REVIEW
Yan Hu, Xiaoting Chen, Xiaojing Chen, Shuang Zhang, Tianyan Jiang, Jing Chang, Yanhong Gao
OBJECTIVE: The purpose of this study was to evaluate the effect of bisphosphonates in improving bone mineral density (BMD) and decreasing the occurrence rate of fractures and adverse events in patients with inflammatory bowel disease (IBD). METHODS: Randomized controlled trials (RCTs) which use bisphosphonates in IBD patients were identified in PubMed, MEDLINE database, EMBASE database, Web of Knowledge, and the Cochrane Databases between 1990 and June 2016. People received bisphosphonate or placebos with a follow-up of at least one year were also considered...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28906290/safety-considerations-with-the-use-of-corticosteroids-and-biologic-therapies-in-mild-to-moderate-ulcerative-colitis
#5
Raymond K Cross
BACKGROUND: The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the safety and tolerability of topically acting corticosteroids and biologic therapies versus oral systemic corticosteroids for ulcerative colitis (UC). METHODS: The PubMed database was searched for clinical and observational trials, systematic reviews, and case reports/series published between January 1950 and September 30, 2016...
October 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28891095/biological-and-clinical-implications-of-herbal-medicine-and-natural-products-for-the-treatment-of-inflammatory-bowel-disease
#6
REVIEW
Bao-Jian Guo, Zhao-Xiang Bian, Hong-Cong Qiu, Yi-Tao Wang, Ying Wang
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders that includes Crohn's disease (CD) and ulcerative colitis (UC). Homeostasis of various regulatory factors involved with intestinal immunity is disrupted in IBD, including the intestinal epithelial barrier, macrophages, and cellular mediators such as cytokines and chemokines. No successful treatment is currently available for the management of IBD. Natural products and herbal medicines have exhibited efficacy for UC and CD in experimental models and clinical trials with the following activities: (1) maintenance of integrity of the intestinal epithelial barrier, (2) regulation of macrophage activation, (3) modulation of innate and adaptive immune response, and (4) inhibition of TNF-α activity...
August 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/28874419/early-intervention-in-crohn-s-disease-towards-disease-modification-trials
#7
REVIEW
Silvio Danese, Gionata Fiorino, Laurent Peyrin-Biroulet
Crohn's disease (CD) is a chronic progressive destructive inflammatory bowel disease. As in rheumatoid arthritis, there is increasing evidence that early treatment initiation with disease-modifying agents, such as biological drugs, may lead to complete disease control, prevention of disease progression thus protecting against irreversible damage and restoration of normal quality of life. Data from randomised clinical trials with immunosuppressants and biologics suggest that treating patients with a disease duration of <2 years and an absence of complications may significantly reduce the risk for complications and increase time in remission in patients with CD...
September 5, 2017: Gut
https://www.readbyqxmd.com/read/28869008/-faecal-microbiota-transplantation-for-the-treatment-of-bowel-disease
#8
Anne A Rode, Mahtab Chehri, Andreas Munk Petersen, Peter Bytzer
Faecal microbiota transplantation (FMT) is the transferral of faeces from a healthy donor to a patient with a disease linked to disturbances in the gut microbiota. The treatment has been implemented at several hospitals in Denmark, and banks with frozen donor stool material have been established. The effect of FMT for recurrent Clostridium difficile infection is well-documented. FMT cannot be recommended for routine clinical use for inflammatory bowel disease and irritable bowel syndrome because of lack of data from clinical trials...
July 31, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28867799/could-pomegranate-juice-help-in-the-control-of-inflammatory-diseases
#9
REVIEW
Francesca Danesi, Lynnette R Ferguson
Fruits rich in polyphenols, such as pomegranates, have been shown to have health benefits relating to their antioxidant and anti-inflammatory properties. Using data obtained from PubMed and Scopus, this article provides a brief overview of the therapeutic effects of pomegranate on chronic inflammatory diseases (CID) such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), metabolic and cardiovascular disorders, and other inflammatory-associated conditions, with an emphasis on fruit-derived juices...
August 30, 2017: Nutrients
https://www.readbyqxmd.com/read/28867793/diet-gut-microbiome-and-epigenetics-emerging-links-with-inflammatory-bowel-diseases-and-prospects-for-management-and-prevention
#10
REVIEW
Krasimira Aleksandrova, Beatriz Romero-Mosquera, Vicent Hernandez
Inflammatory bowel diseases (IBD) represent a growing public health concern due to increasing incidence worldwide. The current notion on the pathogenesis of IBD is that genetically susceptible individuals develop intolerance to dysregulated gut microflora (dysbiosis) and chronic inflammation develops as a result of environmental triggers. Among the environmental factors associated with IBD, diet plays an important role in modulating the gut microbiome, influencing epigenetic changes, and, therefore, could be applied as a therapeutic tool to improve the disease course...
August 30, 2017: Nutrients
https://www.readbyqxmd.com/read/28863833/allergic-diseases-from-bench-to-clinic-contribution-of-the-discovery-of-interleukin-5
#11
REVIEW
Tsutomu Yanagibashi, Mitsuo Satoh, Yoshinori Nagai, Masamichi Koike, Kiyoshi Takatsu
T helper 2 cells produce a number of cytokines including inteleukin (IL)-5, IL-4 and IL-13. Group 2 innate lymphoid cells (ILC2s) also produce IL-5 under sterile conditions. IL-5 is interdigitating homodimeric glycoprotein and a member of the four α helical bundle motifs conserved among hematopoietic cytokines. IL-5 exerts its effects on target cells via IL-5 receptor (IL-5R), composed of an IL-5R α and βc subunit. The membrane proximal proline-rich motif of the cytoplasmic domain of both IL-5R α and βc subunits is essential for IL-5 signal transduction...
October 2017: Cytokine
https://www.readbyqxmd.com/read/28858073/the-current-landscape-and-lessons-from-fecal-microbiota-transplantation-for-inflammatory-bowel-disease-past-present-and-future
#12
Jessica Allegretti, Lindsay M Eysenbach, Najwa El-Nachef, Monika Fischer, Colleen Kelly, Zain Kassam
Fecal microbiota transplantation (FMT) has changed the standard of care for Clostridium difficile infection. However, there is limited data focusing on efficacy and safety profile of FMT in patients with C. difficile infection with underlying inflammatory bowel disease (IBD), including the risk of IBD flare. Recently, there is also emerging evidence supporting the role of FMT to treat IBD including promising randomized trials in ulcerative colitis. However, with heterogeneity across these studies, the clinical application of this emerging therapy has yet to be fully elucidated...
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28858071/efficacy-of-the-autoimmune-protocol-diet-for-inflammatory-bowel-disease
#13
Gauree G Konijeti, NaMee Kim, James D Lewis, Shauna Groven, Anita Chandrasekaran, Sirisha Grandhe, Caroline Diamant, Emily Singh, Glenn Oliveira, Xiaoyun Wang, Bhuvan Molparia, Ali Torkamani
INTRODUCTION: Data suggest dietary modification can improve clinical responses in inflammatory bowel disease (IBD). The goal of this study was to determine the efficacy of an autoimmune protocol diet in patients with Crohn's disease and ulcerative colitis. METHODS: We enrolled adults with active IBD (Harvey-Bradshaw index ≥ 5 or partial Mayo score ≥3 and erosions on endoscopy and/or elevated fecal calprotectin). For the autoimmune protocol, patients underwent 6-week elimination followed by 5-week maintenance phase...
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28852978/unmet-needs-in-ibd-the-case-of-fatigue
#14
REVIEW
Pieter Hindryckx, Debby Laukens, Ferdinando D'Amico, Silvio Danese
Fatigue is a highly prevalent but relatively ignored problem in IBD patients. It is one of the most burdensome symptoms to the patient with an important impact on the quality of life. Therefore, fatigue is a highly relevant patient-reported outcome that should be included not only in disease activity measurement but also in the endpoints of clinical trials in IBD. However, most of the currently available scoring systems to quantify fatigue are not specifically designed for patients with IBD and none of them has undergone a complete validation process for IBD-related fatigue...
August 29, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28852307/treating-children-with-inflammatory-bowel-disease-current-and-new-perspectives
#15
REVIEW
Graziella Guariso, Marco Gasparetto
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gut characterised by alternating periods of remission and relapse. Whilst the mechanism underlying this disease is yet to be fully understood, old and newer generation treatments can only target selected pathways of this complex inflammatory process. This narrative review aims to provide an update on the most recent advances in treatment of paediatric IBD. A MEDLINE search was conducted using "paediatric inflammatory bowel disease", "paediatric Crohn's disease", "paediatric ulcerative colitis", "treatment", "therapy", "immunosuppressant", "biologic", "monitoring" and "biomarkers" as key words...
August 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28827258/protocol-for-a-randomised-placebo-controlled-pilot-study-for-assessing-feasibility-and-efficacy-of-faecal-microbiota-transplantation-in-a-paediatric-ulcerative-colitis-population-pedifetch-trial
#16
Nikhil Pai, Jelena Popov
INTRODUCTION: Ulcerative colitis (UC) is a chronic, relapsing condition characterised by colonic inflammation. Increasing prevalence in early-age diagnosis provides opportunities for additional complications in later life as a result of prolonged exposure to inflammatory and therapeutic insults, necessitating novel avenues for therapeutics which may result in fewer side effects. Faecal microbiota transplantation (FMT) has previously demonstrated potential therapeutic benefit in an adult randomised-controlled trial and several recurrent Clostridium difficile infection studies...
August 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28826742/a-comprehensive-review-and-update-on-crohn-s-disease
#17
Mahesh Gajendran, Priyadarshini Loganathan, Anthony P Catinella, Jana G Hashash
The term inflammatory bowel disease (IBD) refers principally to two major categories of chronic relapsing inflammatory intestinal disorders: Crohn's disease (CD) and ulcerative colitis (UC). In the United States, it is currently estimated that about 1.5 million people suffer from IBD, causing considerable suffering, mortality and economic loss every year. Yet the cause of IBD is unknown, and until we understand more, prevention or cure will not be possible. There is a lot of variation in the incidence and prevalence of CD based on geographic region, environment, immigrant population, and ethnic groups...
August 18, 2017: Disease-a-month: DM
https://www.readbyqxmd.com/read/28792532/continuous-il-23-stimulation-drives-ilc3-depletion-in-the-upper-gi-tract-and-in-combination-with-tnf%C3%AE-induces-robust-activation-and-a-phenotypic-switch-of-ilc3
#18
Amanda M Schmidt Paustian, Jesus Paez-Cortez, Shaughn Bryant, Susan Westmoreland, Wendy Waegell, Gillian Kingsbury
Mutations in the Interleukin (IL)-23/IL-23 receptor loci are associated with increased inflammatory bowel disease (IBD) susceptibility, and IL-23 neutralization has shown efficacy in early clinical trials. To better understand how an excess of IL-23 affects the gastrointestinal tract, we investigated chronic systemic IL-23 exposure in healthy wildtype mice. As expected, IL-23 exposure resulted in early activation of intestinal type 3 innate lymphoid cells (ILC3), followed by infiltration of activated RORγt+ T helper cells...
2017: PloS One
https://www.readbyqxmd.com/read/28791200/a-randomized-clinical-trial-of-vitamin-d3-cholecalciferol-in-ulcerative-colitis-patients-with-hypovitaminosis-d3
#19
Jagrati Mathur, Soe Naing, Paul Mills, David Limsui
AIM: To prospectively evaluate the effects of vitamin D3 on disease activity and quality of life in ulcerative colitis (UC) patients with hypovitaminosis D. METHODS: The study was a prospective double-blinded, randomized trial conducted at Community Regional Medical Center, Fresno, CA from 2012-2013. Patients with UC and a serum 25(OH)D level <30 ng/ml were eligible for the study. Enrolled subjects were randomized to receive either 2,000 IU or 4,000 IU of oral vitamin D3 daily for a total of 90 days...
2017: PeerJ
https://www.readbyqxmd.com/read/28783205/successful-treatment-of-chronic-hepatitis-c-with-ground-ledipasvir-sofosbuvir-in-a-patient-with-crohn-s-disease-and-short-bowel-syndrome
#20
Johann von Felden, Christoph Scheurich, Jin Yamamura, Diana M Brainard, Erik Mogalian, Ansgar W Lohse, Julian Schulze-Zur-Wiesch
We read the comprehensive review by Gitto et al. entitled 'NS5A inhibitors for the treatment of hepatitis C infection' (CHC) with great interest (1). Indeed, the development of direct acting antivirals (DAAs) now enables successful treatment of formerly difficult-to-treat patient populations (e.g. cirrhosis or chronic kidney disease). However, little is known about the use of DAAs in patients with short bowel syndrome, e.g. following inflammatory bowel disease (IBD), because these patients are yet excluded from clinical trials (2)...
August 7, 2017: Journal of Viral Hepatitis
keyword
keyword
74383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"